INCY · News · 20260807N
Acquisition / Partnership / Divestiture
INCYTE CORP · 2026-08-07 · Importance 65 · Surprise 60 · In source text
Incyte acquired Vega Therapeutics, adding VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease. Oppenheimer estimated VGA039 could become a long-term growth asset exceeding $1 billion. The acquisition is expected to diversify Incyte’s revenue base as Jakafi approaches loss of exclusivity and strengthen its hematology franchise. Oppenheimer raised its price target for Incyte to $107 from $90 while maintaining an Outperform rating.
Key facts
- Incyte acquired Vega Therapeutics. source
- The acquisition adds VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease. source
- Oppenheimer increased its price target for Incyte to $107 from $90 and maintained an Outperform rating. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | committed | — | Incyte acquired Vega Therapeutics. |
| revenue | positive | probable | — | The acquisition adds VGA039, a Phase 3-ready Protein S modulator for von Willebrand disease. |